Aceso Life Science expects FY profit of about HK$336 million vs HK$1.02 billion loss a year earlier

• Aceso Life Science guided for profit of about HK$336 million for the year ended March 31, 2026.
• That compares with a loss of about HK$1.02 billion in the prior year.
• The swing to profit was mainly driven by a gain on the disposal of a subsidiary.
• Trading in the shares has been suspended since July 2, 2026, pending release of the annual results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12269555), on August 03, 2026, and is solely responsible for the information contained therein.